Page Title
Drug Development Pipeline
Back to the Drug Development Pipeline
Docosahexaenoic Acid (DHA)
Status
DiscontinuedTherapeutic Approach
Anti-Inflammatory
Docosahexaenoic acid (DHA) is an omega-3 fatty acid with anti-inflammatory properties.
Status
No further clinical development in CF is planned at this time.
Sponsor
The program was fully funded through the Cystic Fibrosis Foundation.
Recent Changes
10/1/2012
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More